All patients
Age < 65y (younger) Age > 65y Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
classical Hodgkin lymphoma (cHL), pembrolizumab based treatment vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results KEYNOTE-204, 2021 0.65 [0.48; 0.88]
0.65 [0.48 ; 0.88 ] KEYNOTE-204, 2021 1 0% 304 NA not evaluable objective responses (ORR)detailed results KEYNOTE-204, 2021 1.68 [1.05; 2.68]
1.68 [1.05 ; 2.68 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-204, 2021 1.55 [0.26; 9.42]
1.55 [0.26 ; 9.42 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable TRAE (any grade)detailed results KEYNOTE-204, 2021 0.87 [0.51; 1.47]
0.87 [0.51 ; 1.47 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.70 [0.40; 1.21]
0.70 [0.40 ; 1.21 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-204, 2021 0.75 [0.39; 1.43]
0.75 [0.39 ; 1.43 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 4.15 [0.19; 92.82]
4.15 [0.19 ; 92.82 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.06; 16.58]
1.03 [0.06 ; 16.58 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.51 [0.02; 15.37]
0.51 [0.02 ; 15.37 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 4.15 [0.19; 92.82]
4.15 [0.19 ; 92.82 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Eczema TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.51 [0.02; 15.37]
0.51 [0.02 ; 15.37 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.51 [0.02; 15.37]
0.51 [0.02 ; 15.37 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.51 [0.02; 15.37]
0.51 [0.02 ; 15.37 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.51 [0.02; 15.37]
0.51 [0.02 ; 15.37 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.17 [0.01; 3.39]
0.17 [0.01 ; 3.39 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.17 [0.01; 3.39]
0.17 [0.01 ; 3.39 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.27 [0.07; 0.97]
0.27 [0.07 ; 0.97 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 0.25 [0.01; 5.69]
0.25 [0.01 ; 5.69 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.14; 7.39]
1.03 [0.14 ; 7.39 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 6.38 [0.76; 53.66]
6.38 [0.76 ; 53.66 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 1.03 [0.02; 52.11]
1.03 [0.02 ; 52.11 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 4.15 [0.19; 92.82]
4.15 [0.19 ; 92.82 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Urticaria TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-204, 2021 2.06 [0.07; 61.91]
2.06 [0.07 ; 61.91 ] KEYNOTE-204, 2021 1 0% 300 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-05 18:25 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 73,232,233
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561